Taken together, these data suggest that patients with myeloid malignancies may acquire RCs of unknown origin through cell cycle instability resulting from loss of function (LOF) TP53 mutations combined with CNL of TP53 at 17p13.1. The gene discussed is TP53; the disease is myeloid neoplasm.